Best Fit Profiles
- NAD+ support as a cost-effective precursor; lipid management under medical guidance
NAD+ precursor and lipid metabolism
Niacin (Vitamin B3)
Niacin is a direct NAD+ precursor and has decades of evidence for raising HDL and lowering triglycerides. AIM-HIGH and HPS2-THRIVE trials showed cardiovascular benefit over statins was not additive. NAD+ elevation is dose-dependent.
Evidence Level A
Evidence and Risk Labels
Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.
See full scoring guideClinical Snapshot
- Effect Size
- Large lipid effects; moderate NAD+ elevation; cardiovascular clinical benefit disputed in statin-treated populations
- Safety
- Moderate Risk
High-dose niacin (>500 mg) causes flushing, liver stress, and blood sugar elevation. Flush-free (inositol hexanicotinate) has poor efficacy. Extended-release forms have liver risk. NR and NMN are cleaner NAD+ boosters.
Research Dosing
This reflects common ranges and protocols used in published studies, not personal medical advice.
- Typical Daily Dose
- 50-500 mg for NAD+ support; 1000-2000 mg for lipids (medical use)
- Timing
- With meals
- Protocol Duration in Studies
- Ongoing with monitoring at higher doses
For NAD+ support, NMN or NR are preferred over high-dose niacin due to better safety at equivalent efficacy.